Detalhe da pesquisa
1.
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
Blood
; 137(3): 323-335, 2021 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32967009
2.
Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure.
Blood
; 135(19): 1650-1660, 2020 05 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32076701
3.
High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy.
Blood
; 134(7): 636-640, 2019 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31648294
4.
Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.
Blood
; 133(15): 1652-1663, 2019 04 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30728140
5.
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.
Blood
; 133(17): 1876-1887, 2019 04 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-30782611
6.
Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency.
Sci Transl Med
; 14(631): eabg8070, 2022 02 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35138909
7.
Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways.
Oncotarget
; 8(49): 84697-84713, 2017 Oct 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-29156677